{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-056806","form_type":"8-K","ticker":"ORMP","cik":"0001176309","company_name":"ORAMED PHARMACEUTICALS INC.","filed_at":"2023-07-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.315175+00:00","generated_at":"2026-06-13T08:36:49.355805+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Oramed stockholders re-elect all six director nominees and ratify auditor at 2023 annual meeting","bullets":["Stockholders re-elected Miriam Kidron, Nadav Kidron, Arie Mayer, Yadin Rozov, Leonard Sank, Benjamin Shapiro as directors.","Highest votes for Benjamin Shapiro (9,239,878 for); lowest for Leonard Sank (8,696,513 for); broker non-votes ~7.7M on each.","Ratified Kesselman & Kesselman (PwC) as independent auditor for FY2023 with 16,991,347 for, 50,052 against, 71,751 abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-056806","json":"https://secwatch.observer/filing/0001213900-23-056806.json","markdown":"https://secwatch.observer/filing/0001213900-23-056806.md","text":"https://secwatch.observer/filing/0001213900-23-056806.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1176309/000121390023056806/0001213900-23-056806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1176309/000121390023056806/ea181769-8k_oramedpharm.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T08:36:49.355805+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"54ca9998193def106f63daabaaacd4c68f2bc8e0","claim":"ORAMED PHARMACEUTICALS INC. shareholders approved Re-election of Directors at the 2023-07-13 meeting.","evidence_excerpt":"Proposal No. 1 — Re-election of Directors. The stockholders re-elected the following directors of the Company to hold office until the next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal. The votes were as follows: Director Name For Against Abstain Broker Non-Votes Dr. Miriam Kidron 9,157,849 173,775 74,353 7,707,173 Nadav Kidron 9,182,326 168,225 55,426 7,707,173 Dr. Arie Mayer 8,920,370 438,226 47,381 7,707,173 Yadin Rozov 8,949,343 411,701 44,933 7,707,173 Leonard Sank 8,696,513 654,931 54,533 7,707,173 Benjamin Shapiro 9,239,878 120,124 45,975 7,707,173","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390023056806/0001213900-23-056806-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-07-13"}],"fact_type":"shareholder_vote"},{"claim_id":"9e8a60c86143a7f0d3288bae7220d7738696b12f","claim":"ORAMED PHARMACEUTICALS INC. shareholders approved Ratification of Independent Registered Public Accounting Firm for the 2023 Fiscal Year at the 2023-07-13 meeting.","evidence_excerpt":"Proposal No. 2 — Ratification of Independent Registered Public Accounting Firm for the 2023 Fiscal Year. The stockholders ratified the appointment of Kesselman & Kesselman, certified public accountants in Israel, a member of PricewaterhouseCoopers International Limited, as the independent registered public accounting firm of the Company for the 2023 fiscal year. The votes were as follows: For Against Abstain Broker Non-Votes 16,991,347 50,052 71,751 -","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390023056806/0001213900-23-056806-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-07-13"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}